A Landmark Waterfront Restaurant Just Closed Out of the Blue
This is a curated list of the Bay Area's most notable and permanent restaurant and bar closures, with new updates published once a week. See a closing we missed? Then drop us a line . For more news, check out our list of restaurants that closed earlier this spring . June 3
EMBARCADERO — An iconic waterfront restaurant closed permanently on Friday, May 30. The team at Fog City, opened in 1985, let diners know of the shuttering in an Instagram post. No reason was given for the closure. The San Francisco Chronicle writes founders Bill Higgins and Bill Upson established the restaurant, then known as Fog City Diner, as a power player early into its tenure with chef Cindy Pawlcyn's (at the time) innovative small plates and Pat Kuleto design.
OAKLAND — Friday, May 9 was the final day of service for chef Mohammad Abutaha's Teta Nahla. The 2123 Franklin Street restaurant was the founder of Shawarmaji's homage to his Jordanian grandmother. Abutaha told fans he hopes to reopen the hotspot for Arab soul food, including dishes like mansaf, once he's done giving his Shawarmaji restaurants his full energy.
NOVATO — Another decades-old Bay Area standby, Marin County's Moylan's Brewery & Restaurant closed for good on Sunday, May 4. SFGATE reports the brewery collected more than 100 gold medals for its brews throughout its tenure. The spot, also beloved for Irish nachos and burgers, closed due to a changing beer landscape. 'You know, the beer business has changed — there's oversaturation — and our younger clientele is doing things differently now,' owner-brewer Brendan Moylan told the outlet.
PETALUMA — The Press Democrat reports a three-year-old outpost of local chain Superburger closed on Thursday, May 29. The business's website let fans know the lease ended and the Sonoma County-based company simply chose not to renew. The other two outposts remain open.
Sign up for our newsletter.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
$1.2 bN Human Microbiome-based Drugs and Diagnostics Global Markets, 2022-2024 & 2025-2030
The human microbiome-based drugs and diagnostics market is projected to grow from $393.4M in 2025 to $1.2B by 2030, at a CAGR of 25.6%. Key players include Ferring, Nestlé Health Science, and Vedanta Biosciences. The report covers market trends, competitive landscape, and ESG developments. Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Human Microbiome-based Drugs and Diagnostics: Global Markets" report has been added to global market for human microbiome-based drugs and diagnostics is expected to grow from $393.4 million in 2025 to reach $1.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 25.6% from 2025 through 2030. The report discusses emerging technologies and analyzes the competitive landscape, providing the ranking/market shares of leading companies in the market. It also includes a chapter on environmental, social and corporate governance (ESG) microbiome-based drugs and diagnostics are novel approaches to tackling difficult-to-treat diseases. The growing understanding of the human microbiome can be leveraged to fill the gaps in conventional treatment options. A wide range of scientific studies have demonstrated the role of microbiomes in the pathogenesis of various diseases. The microbiome field is also witnessing an increased level of investments from the private and public sectors. Future opportunities in the market lie in exploring microbiomes in other body parts, such as lungs, and developing microbiome-based drugs as combination therapies. Leading companies in the market for human microbiome-based drugs and diagnostics include Ferring, Nestle Health Science (Seres Therapeutics), BiomeBank, Genetic Analysis AS and Vedanta Scope 55 data tables and 51 additional tables Analyses of the trends in global markets for human microbiome-based drugs and diagnostics, with revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030 Estimates of the size and revenue prospects for the global market, along with a market share analysis by type, drug route of administration, diagnostics product type, application, end user, and region Facts and figures pertaining to market dynamics, opportunities and deterrents, technological advances, regulations, and the impacts of macroeconomic variables Review of the prevalence of infectious diseases, metabolic disorders and chronic ailments An assessment of current products, clinical trials and identification of new potential markets for novel products and assay development Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings, and consumer attitudes An analysis of the key patent grants and recently published patents Analysis of the industry structure and value chain, and the competitive landscape, including companies' market shares, strategic alliances, M&A activity, venture fundings and investment outlook Profiles of the leading companies, including Ferring Pharmaceuticals, Nestle Health Science, BiomeBank, Genetic Analysis AS, and Vedanta Biosciences Inc. Companies Featured BiomeBank EnteroBiotix Ltd. Enterome Ferring Genetic Analysis Illumina Inc. Microbiome Insights Microbiotica Nestle Health Science Oxford Nanopore Technologies plc PacBio SFA Therapeutics Inc. Thermo Fisher Scientific Inc. Vedanta Biosciences Inc. Key Topics Covered: Chapter 1 Executive Summary Market Outlook Scope of Report Market Summary Market Dynamics Emerging Technologies Analysis by Segment Regional Analysis Conclusion Chapter 2 Market Overview Overview and Market Definition Different Microbiomes in Humans Microbiome, Human Health and Disease Technologies Aiding Microbiome Research Culturing and Cultivation Strategies for the Development of Microbiome Therapeutics Additive Microbiome Therapy Modulatory Microbiome Therapy Analysis of Macroeconomic Factors Geopolitical Factors Inflation and Currency Exchange Fluctuations Porter's Five Forces Analysis Chapter 3 Market Dynamics Takeaways Market Drivers Growing Evidence of Microbiome-disease Correlation Microbiome-based Diagnostics for Disease Prevention and Monitoring Market Restraints Challenges in Clinical Trial Design Lack of Established Regulatory Frameworks High Costs of Microbiome Therapeutics Market Opportunities Direct-to-Consumer Microbiome Testing Drugs and Diagnostics for Lung and Skin Microbiomes Chapter 4 Regulatory Landscape Regulatory Aspects North America Europe Asia-Pacific Chapter 5 Emerging Technologies Takeaways Emerging Technologies Microbial Ecosystem Therapeutics Metatranscriptome Sequencing Genetically Modified Microbiome Therapeutics Combination and Adjuvant Therapies with Microbiome-based Drugs Novel Preclinical Models Chapter 6 Market Segmentation Analysis Segmentation Breakdown Market Analysis by Type Microbiome-based Drugs Market Analysis by Application Infectious Diseases GI Disorders Metabolic Disorders Cancer Other Diseases Market Analysis by End User Hospitals and Clinics Research Institutions Pharmaceutical Companies Geographic Breakdown Market Analysis by Region North America Europe Asia-Pacific South America Middle East and Africa Chapter 7 Competitive Intelligence Takeaways Company Share Analysis Competitive Analysis Venture Funding and Investment Landscape Recent Developments Chapter 8 Sustainability in the Human Microbiome-based Drugs and Diagnostics Industry: An ESG Perspective Introduction to ESG ESG Risk Ratings Concluding Remarks Chapter 9 Appendix For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
23 minutes ago
- Yahoo
Citigroup to axe around 3,500 tech roles in China
Citigroup is trimming its workforce size by approximately 3,500 at two of its technology centres in China, reported Reuters. The aim is to consolidate and streamline the bank's global technology operations to enhance its risk and data management systems. The staffing reductions will affect the China Citi Solution Centres in Shanghai and Dalian, with the bank planning to complete the process by the start of the fourth quarter of this year, the news agency said citing a statement by Citi. The jobs being cut are predominantly full-time positions, a source privy to the development disclosed. Some of the jobs from these centres would be relocated to other technology hubs within the company, although the specifics regarding the number of jobs or their destinations were not provided. This announcement follows last month's report, which indicated that Citigroup was reducing around 200 information technology contractor roles in China. In March, the bank communicated internally its strategy to decrease its reliance on IT contractors and to increase its in-house IT staff, in response to penalties imposed by regulators concerning data governance and control shortcomings. The downsizing in China is part of Citigroup's global restructuring plan, which has also seen the bank scaling back operations in the US, Indonesia, the Philippines, and Poland. The China-based service and technology unit is tasked with delivering financial technology and operations services to support Citigroup's global business operations. Citigroup is currently in the process of establishing a securities unit in China, still maintain the regional presence. Post-reduction, Citigroup's staff count in China is expected to be around 2,000, which includes several hundred employees within the technology division. Citi Japan, Asia North and Australia banking head Marc Luet was quoted by Reuters as saying: "Citi continues to pursue the establishment of a wholly owned securities and futures company in China." "Citigroup to axe around 3,500 tech roles in China " was originally created and published by Retail Banker International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
36 minutes ago
- Yahoo
British Airways says its short-haul business class is booming. Here's why that could be a boost for US budget airlines.
British Airways' CEO said Club Europe sales have "defied our best expectations." The premium cabin has the same seats as economy, but with the middle one blocked off. Spirit Airlines is introducing a similar product as fliers are more interested in upgrades globally. European-style business class isn't the most luxurious, but its popularity has reached new heights at British Airways. British Airways CEO Sean Doyle said sales in its Club Europe class have "defied our best expectations," The Times of London reported on Tuesday. While legacy US airlines offer comfier seats and more legroom on all their aircraft, most European carriers have a much simpler premium product on their narrow-body planes. In the typical 3-3 layout, business class simply has a divider placed on the middle seat. A curtain separating it from the economy cabin can be moved down the aisle depending on capacity. "After the global financial crisis in 2008, people were saying it wouldn't work," Doyle reportedly said at the International Air Transport Association conference. "And yet it's more popular than ever, especially for leisure passengers." He pointed to perks like lounge access, priority boarding, and better food-and-drink options. "There is really important value in short-haul premium for customers, and we are seeing that come through in the numbers," Doyle added, per The Times. The fact that the hard product — the seat itself — is so similar to traveling in economy means some Europeans don't see the value compared to flying with a budget airline like easyJet or Ryanair. However, premium options have been in more demand around the world since the pandemic. That's strained budget airlines, especially in the US. They've been rolling out upgraded offerings in an attempt to attract more customers as their preferences have changed. For example, Doyle's comments could be particularly welcomed by Spirit Airlines. Last July, it announced a "Go Comfy" option that would include a blocked middle seat in the same style as British Airways' Club Europe. However, unlike the London-based carrier, "Go Comfy" seats will also have four inches of extra legroom. Southwest Airlines has also announced premium options, scrapping its signature unassigned-seating policy to encourage passengers to pay for extra legroom. At the Bernstein Strategic Decisions Conference last week, CEO Bob Jordan said customers want different cabins, a variety of offerings, and "access to premium." Doyle's comments suggest that the American budget airlines are on the right path. Even if their offerings aren't as opulent as Delta Air Lines or United Airlines, passengers simply care more about the experience of flying in a premium class. Read the original article on Business Insider Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
